D. Beight

发表

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

M. Vieth, R. Campbell, B. Anderson, 2003, Journal of medicinal chemistry.

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

R. Campbell, B. Anderson, Faming Zhang, 2004, Bioorganic & medicinal chemistry letters.

1,2-Dibenzamidobenzene inhibitors of human factor Xa.

J. A. Kyle, J. Wikel, B. Eastwood, 2000, Journal of medicinal chemistry.

N(2)-Aroylanthranilamide inhibitors of human factor Xa.

J. A. Kyle, T. Goodson, T. Craft, 2000, Journal of medicinal chemistry.

1,2-Dibenzamidobenzene inhibitors of human factor Xa.

J. A. Kyle, J. Wikel, B. Eastwood, 2000, Journal of medicinal chemistry.

A DEHYDROALANINE ROUTE TO AN ACTIVATED PHENOLIC SPARSOMYCIN ANALOG

D. Beight, G. Flynn, 1984 .

The synthesis of fluorinated aminophosphonic acid inhibitors of alanine racemase

D. Beight, B. Metcalf, E. Bohme, 1985 .

Synthesis of constrained thiorphan analogs as inhibitors of neutral endopeptidase

D. Beight, G. Flynn, S. Mehdi, 1996 .

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Xiaohong Xu, Philip W. Iversen, David K. Clawson, 2017, Oncotarget.

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

M. Kalos, Xiaohong Xu, B. Anderson, 2017 .

Interaction of angiotensin I-converting enzyme with two potent tricyclic inhibitors.

D. Beight, E. Giroux, R. C. Dage, 1989, Journal of enzyme inhibition.

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.

S. A. Watkins, H. Brooks, J. Yingling, 2005, Biochemistry.

Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11.

D. Beight, E. Giroux, J. F. French, 1993, Journal of Medicinal Chemistry.

“An efficient synthesis of ethyl (R)-2-hydroxy-4-phenylbutyrate: A useful intermediate in the synthesis of converting enzymeinhibitors”

D. Beight, G. Flynn, 1988 .

Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives.

Y. H. Do, D. Beight, V. Klimkowski, 2005, Thrombosis research.

Importance of the hydrophobic sulfoxide substituent on nontoxic analogs of sparsomycin

D. Beight, G. Flynn, R. Ash, 1984, Antimicrobial Agents and Chemotherapy.